In a groundbreaking revelation at the 2024 International Stroke Conference, the GOLDEN BRIDGE II trial showcased AI-CDSS’s transformative impact on acute ischemic stroke (AIS) care. With over 20,000 patients, those on AI-CDSS experienced a significant 2.9% reduction in composite vascular events at 3 months.
Source NeurologyLive
